Hospital

In an ambitious effort to address the ongoing uncertainty within the 340B Program space, 6 senators released a draft discussion bill earlier this year titled the SUSTAIN Act.

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Pharmacists can get involved by counseling patients on when to halt use of supplements, as well as proper use and selection of products.

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

Christie Smith discusses navigating state pharmacy laws and advocating for policy changes to improve patient access and care coordination.

The results reinforce other real-world evidence from several broad infant immunization programs in the US, Spain, and France.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

The investigators note that additional research is needed to confirm positive overall survival trends in this patient population.

The 1-time treatment may be a better alternative for patients who don’t want to undergo frequent doses of standard of care intravenous factor IX infusions.

Prevention of acute cardiac events may be another consideration for future postlicensure studies of RSV vaccines.

Vitamin D deficiency (VDD) is an important factor in the pathogens of schizophrenia.

Pharmacists can help patients distinguish between food allergies and intolerances, as well as facilitate access to life-saving medications and preventative care.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Trastuzumab is indicated for adjuvant breast cancer, metastatic breast cancer, and gastric cancer.

Vincent Young, MD, PhD, shares takeaways from Peggy Lillis Foundation's 2024 National C diff Advocacy Summit.

The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

On this month's episode Laura Gillespie, PharmD, discusses her paper “Impact of Pharmacist-Led Initiatives on Health Care–Associated Clostridioides difficile Rates.”

The severity of RSV disease among adults further highlights how crucial vaccine polices and recommendations are.

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.